Table 1.
Proteomic marker | Cancer type | Clinical use | Detection method | References |
---|---|---|---|---|
PRDX6 and ANXA11 | Prostate | Diagnosis | 2D-PAGE | Ummani et al., 201515 |
ANX1, HP, AZGP1 and calprotectin | Lung | Diagnosis | 2D-DIGE | Xiao et al., 201217 |
SMR | Prostate | Prognosis | Mass spectrometry | Kwon et al., 202021 |
APOCH1, CAH1 and NCHL1 | Breast | Diagnosis and prognosis | Mass spectrometry | Kim et al., 201922 |
HSP70 | Breast | Prediction | ELISA | Rothammer et al., 201928 |
HSP90α | Pan cancer | Diagnosis | ELISA and western blot | Liu et al., 201930 |
CLDN2, CLDN6, CLDN11 and CLDN14 | Breast | Prognosis | Western blot | Jia et al., 201934 |
Netrin-1 | Breast | Diagnosis | Western blot | El-Gamal et al., 202036 |
CRP, prolactin, HGF and autoantigen NY-ESO-1 | Lung | Diagnosis | Multiplexed ELISA | Ma et al., 201637 |
AMACR | Prostate | Diagnosis | ELISA | Etheridge et al., 201838 |
Urinary plasminogen and fibrinogen gamma | Prostate | Diagnosis | ELISA | Zhang et al., 202039 |
HE4 and TTR | Ovarian | Diagnosis | ELISA | Zheng et al., 201840 |
ZNF71 | Lung | Prognosis | Immunohistochemistry | Guo et al., 201841 |
TTF1, p40, PD-L1 | Lung | Diagnosis and prognosis | Immunohistochemistry | Llie et al., 201842 |